Predecessor Appln. No.: 10/068,514

Predecessor Filing Date: February 5, 2002

Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application:

Claims 1-21. (Cancelled).

Claim 22 (New): A pharmaceutical composition comprising:

1 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or

a tautomer thereof, in a pharmaceutically acceptable form, and

a pharmaceutically acceptable carrier therefor.

Claim 23 (New): The pharmaceutical composition according to claim 22 comprising 1 mg of 5-

[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer

thereof.

Claim 24 (New): The pharmaceutical composition according to claim 22 comprising 2 mg of 5-

[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer

thereof.

Claim 25 (New): The pharmaceutical composition according to claim 22 comprising 4 mg of 5-

[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer

thereof.

Claim 26 (New): The pharmaceutical composition according to claim 22 comprising 8 mg of 5-

[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer

thereof.

Claim 27 (New): The composition according to claim 22 wherein the pharmaceutically

acceptable form of said compound is a pharmaceutically acceptable salt.

Claim 28 (New): The composition according to claim 27 wherein the salt is a maleate salt.

3

Predecessor Appln. No.: 10/068,514

Predecessor Filing Date: February 5, 2002

Claim 29 (New): The composition according to claim 22 wherein the pharmaceutically acceptable form of said compound is a pharmaceutically acceptable solvate.

Claim 30 (New): The composition according to claim 29 wherein the solvate is a hydrate.

Claim 31 (New): The composition according to claim 22 wherein the pharmaceutically acceptable form of said compound is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt.

Claim 32 (New): The composition according to claim 31 wherein the salt is a maleate salt.

Claim 33 (New): The composition according to claim 31 wherein the solvate is a hydrate.

Claim 34 (New): The composition according to claim 22, wherein the compositions is adapted for oral administration.

Claim 35 (New): The composition according to claim 22, wherein said composition is in the form of a tablet or capsule.

Claim 36 (New): The composition according to claim 22, wherein the pharmaceutically acceptable carrier comprises a disintegrant, a binder, and a diluent.

Claim 37 (New): The composition according to claim 22, wherein the pharmaceutically acceptable carrier comprises sodium starch glycollate.

Claim 38 (New): The composition according to claim 22, wherein the pharmaceutically acceptable carrier comprises methyl cellulose.

Claim 39 (New): The composition according to claim 22, wherein the pharmaceutical acceptable carrier comprises a cellulose or lactose monohydrate.

Predecessor Appln. No.: 10/068,514 Predecessor Filing Date: February 5, 2002

Claim 40 (New): The composition according to claim 22, wherein the pharmaceutically acceptable carrier comprises: sodium starch glycollate, hydroxpropylmethyl cellulose 2910, microcrystalline cellulose, and lactose monohydrate.

Claim 41 (New): The composition according to claim 22, wherein the pharmaceutically acceptable carrier comprises: sodium starch glycollate, hydroxpropylmethyl cellulose 2910, microcrystalline cellulose, and lactose monohydrate.

Claim 42 (New): The composition according to claim 22, wherein the pharmaceutically acceptable carrier comprises a binding agent selected from syrup, acacia, gelatin, sorbitol, tragacanth, and polyvinylpyrollidone.

Claim 43 (New): The composition according to claim 22, wherein the pharmaceutically acceptable carrier comprises a disintegrant selected from starch, polyvinylpyrrolidone, sodium starch glycollate, and microcrystalline cellulose.

Claim 44 (New): The composition according to claim 22, wherein the pharmaceutically acceptable carrier comprises at least one of sodium lauryl sulphate and magnesium stearate.

Claim 45 (New): The composition according to claim 22, wherein the pharmaceutically acceptable carrier comprises at least one of lactose, sugar, maize-starch, calcium phosphate, sorbitol, and glycine.